cytochrome P450 family 19 subfamily A member 1Genealiases: ARO · ARO1 · CPV1 · CYAR · CYP19 · CYPXIX
Q-omics provides the consensus-scored CYP19A1 profile across patient tissues and cancer cell-line models. CYP19A1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CYP19A1 is differentially expressed in 12, with the highest sampling consensus in STAD. Additionally, CYP19A1 RNA expression shows 13,090 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight HNSC, STAD, and READ as cancer lineages where CYP19A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP19A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP19A1 survival associations across molecular data types. CYP19A1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP19A1 RNA expression–survival associations across cancer types. High CYP19A1 expression shows unfavorable associations in HNSC, LIHC, STAD, LUAD and KIRC, but favorable associations in UVM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CYP19A1 RNA expression.
This table summarizes CYP19A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYP19A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP19A1 shows lower tumor expression in THCA and higher tumor expression in STAD, KIRP, LUAD, COAD and HNSC. The STAD box plot shows higher CYP19A1 RNA expression in tumor versus normal tissue (log2 FC = +0.318, t-test p < 0.001).
This table shows molecular features associated with CYP19A1 in patient tissues and cancer cell lines. In patient samples, CYP19A1 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP19A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
